Long-term immunity induced by SPBN GASGAS in orally vaccinated dogs is non-inferior to inactivated rabies vaccines

Ad Vos; Suwicha Kasemsuwan; Kansuda Leelahapongsathon; Katharina Bobe; David Perez-Bravo; Jeannette Kliemt; Parinya Phawaphutayanchi; Nirut Aiyara; Conrad M Freuling; Thomas Müller

doi:10.1016/j.jvacx.2023.100410

Long-term immunity induced by SPBN GASGAS in orally vaccinated dogs is non-inferior to inactivated rabies vaccines

Vaccine X. 2023 Nov 21:15:100410. doi: 10.1016/j.jvacx.2023.100410. eCollection 2023 Dec.

Affiliations

¹ Ceva Innovation Center, 06861 Dessau-Rosslau, Germany.
² Faculty of Veterinary Medicine, Kasetsart University, Bangkok 10900, Thailand.
³ Institute of Molecular Virology and Cell Biology, Friedrich-Loeffler-Institut (FLI), WHO Collaborating Centre for Rabies Surveillance and Research, 17493 Greifswald-Insel Riems, Germany.
⁴ Department of Health, Bangkok Metropolitan, Thapthan 61120, Thailand.

Abstract

In a long-term immunogenicity study (1100 days post vaccination) in local Thai dogs the immune response of the oral rabies vaccine SPBN GASGAS was compared to those elicited by a commercial inactivated vaccine using immunobridging. Based on the detection of rabies virus binding (rVBA) and rabies virus neutralizing antibodies (rVNA) as measured by ELISA and Rapid Fluorescent Focus Inhibition Test (RFFIT) the long-term immune response in dogs vaccinated orally with the SPBNA GASGAS strain of rabies vaccine in a bait was non-inferior to a conventional inactivated rabies vaccine. The outcome of this study supports extending the originally claimed duration of immunity (DOI) of SPBN GASGAS after oral vaccination for dogs from 6 to 30 months.

Keywords: DOI; Dog; Efficacy; Immunobridging; Oral vaccination; SPBN GASGAS.